RO Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Roche Holding (SWX: RO)
›
Roche Holding (SWX: RO) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.
The shares were at 406.80 CHF on 19 November 2026, up 39.9% over 52 weeks. Its 52-week range is 297.20 CHF to 417.80 CHF: the price is 2.6% below the high and 36.9% above the low.
At a market capitalisation of 322.69B CHF, it trades at 26.4 times trailing earnings and 18.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - General peers is 25.4, so RO is valued in line with them. It pays a dividend yielding 2.40% (it pays out 64% of its earnings), against a median of 2.68% among the dividend payers in that peer group.
Roche Holding reports return on equity of 38.1%, an operating margin of 33.1% and revenue down 1.2% year over year.
Its debt exceeds its cash by 23.57B CHF, a debt-to-equity ratio of 0.98. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 470.00 CHF is 15.5% above the current price.